Cargando…
Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia
Background: Tofacitinib is the first Janus kinase (JAK) inhibitor approved for treating rheumatoid arthritis (RA). Several clinical trials have evaluated the safety and effectiveness of tofacitinib in adult patients with moderately to severely active RA. Real-world studies provide invaluable insight...
Autores principales: | Alzahrani, Zeyad, Alhazmi, Ahmed, Almalki, Hanan, Aljehani, Noura, Dumyati, Mohammed, Alabdali, Hadeel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813543/ https://www.ncbi.nlm.nih.gov/pubmed/36620821 http://dx.doi.org/10.7759/cureus.32240 |
Ejemplares similares
-
Prevalence of Latent Tuberculosis Infection (LTBI) in Mexican Patients With Rheumatoid Arthritis (RA)
por: Zavala del Ángel, Abel Eduardo, et al.
Publicado: (2023) -
Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
por: Movahedi, Mohammad, et al.
Publicado: (2023) -
Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis
por: Gilbert, Benoit Thomas P, et al.
Publicado: (2021) -
Weight Gain in Seropositive Rheumatoid Arthritis Patients Treated With Anti-tumor Necrosis Factor (TNF) Therapy
por: Alsulaim, Toka M, et al.
Publicado: (2022) -
Biomarkers in Rheumatoid Arthritis
por: Shapiro, Samantha C
Publicado: (2021)